🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 4 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 02/10/1992 | 5,00 | 5,25 | 5,00 | 5,00 | +0,00% | 5,00% | 22.000 |
| 01/10/1992 | 5,00 | 5,38 | 5,00 | 5,00 | -5,88% | 7,50% | 29.600 |
| 30/09/1992 | 5,00 | 5,38 | 5,00 | 5,31 | +1,19% | 7,50% | 11.600 |
| 29/09/1992 | 5,13 | 5,38 | 5,00 | 5,25 | +1,20% | 7,32% | 220.000 |
| 28/09/1992 | 5,13 | 5,38 | 5,13 | 5,19 | +1,22% | 4,88% | 143.400 |
| 25/09/1992 | 5,19 | 5,38 | 5,00 | 5,13 | +2,50% | 7,23% | 192.000 |
| 24/09/1992 | 5,00 | 5,25 | 5,00 | 5,00 | +0,00% | 5,00% | 89.800 |
| 23/09/1992 | 5,00 | 5,25 | 5,00 | 5,00 | +0,00% | 5,00% | 7.200 |
| 22/09/1992 | 5,38 | 5,38 | 5,00 | 5,00 | -6,98% | 6,98% | 20.000 |
| 21/09/1992 | 5,38 | 5,38 | 5,13 | 5,38 | +4,88% | 4,65% | 15.200 |
| 18/09/1992 | 5,13 | 5,25 | 5,13 | 5,13 | +0,00% | 2,44% | 8.400 |
| 17/09/1992 | 5,38 | 5,50 | 5,13 | 5,13 | -4,65% | 6,98% | 105.800 |
| 16/09/1992 | 5,38 | 5,63 | 5,38 | 5,38 | -2,27% | 4,65% | 25.200 |
| 15/09/1992 | 5,50 | 5,75 | 5,50 | 5,50 | +0,00% | 4,55% | 10.600 |
| 14/09/1992 | 5,50 | 5,75 | 5,50 | 5,50 | +2,33% | 4,55% | 36.400 |
| 11/09/1992 | 5,38 | 5,63 | 5,38 | 5,38 | -2,27% | 4,65% | 75.400 |
| 10/09/1992 | 5,38 | 5,63 | 5,38 | 5,50 | +0,00% | 4,65% | 42.200 |
| 09/09/1992 | 5,38 | 5,63 | 5,13 | 5,50 | +2,33% | 9,30% | 161.800 |
| 08/09/1992 | 5,25 | 5,38 | 5,00 | 5,38 | +7,50% | 7,14% | 231.800 |
| 04/09/1992 | 5,00 | 5,25 | 5,00 | 5,00 | -2,44% | 5,00% | 146.000 |
| 03/09/1992 | 5,00 | 5,13 | 4,88 | 5,13 | +3,80% | 5,00% | 270.400 |
| 02/09/1992 | 5,13 | 5,13 | 4,75 | 4,94 | -2,47% | 7,32% | 49.600 |
| 01/09/1992 | 4,75 | 5,13 | 4,63 | 5,06 | +6,58% | 10,53% | 93.400 |
| 31/08/1992 | 4,38 | 4,75 | 4,38 | 4,75 | +5,56% | 8,57% | 11.600 |
| 28/08/1992 | 4,63 | 4,75 | 4,38 | 4,50 | -1,37% | 8,11% | 15.400 |
| 27/08/1992 | 4,63 | 4,63 | 4,25 | 4,56 | -1,35% | 8,11% | 149.400 |
| 26/08/1992 | 4,38 | 4,63 | 4,38 | 4,63 | +0,00% | 5,71% | 400 |
| 25/08/1992 | 4,50 | 4,63 | 4,38 | 4,63 | +2,78% | 5,56% | 7.800 |
| 24/08/1992 | 4,50 | 4,50 | 4,50 | 4,50 | +0,00% | 0,00% | 11.400 |
| 21/08/1992 | 4,75 | 4,75 | 4,50 | 4,50 | -7,69% | 5,26% | 37.800 |